Accentia Biopharmaceutical, Inc. (ABPI) Announced Revimmune™ Has Been Awarded Frost & Sullivan Multiple Sclerosis Product Innovation Reward
Accentia Biopharmaceuticals, Inc, a vertically integrated biopharmaceutical company, announced March 13th that Revimmune™, the company’s potential therapeutic for refractory, relapsing-remitting Multiple Sclerosis (MS). If approved will be the first product capable of restoring neurological function, and has been awarded the Frost & Sullivan Multiple Sclerosis Product Innovation of the Year Award, which is presented to companies in recognition for an outstanding contribution. The Company’s intent is to file an Investigational New Drug Application, with a goal to commence Phase 3 MS clinical trials this year. Barath Shankar Subramanian, Frost & Sullivan Analyst commented, “The primary endpoint of Accentia’s planned Revimmune Phase…